BUZZ-OraSure rises after Bundibugyo Ebola test receives US FDA emergency use nod

OraSure Technologies, Inc.

OraSure Technologies, Inc.

OSUR

0.00

** Shares of diagnostic test maker OraSure Technologies OSUR.O rise 4.2% to $3.96 premarket

** Co says it has received Emergency Use Authorization (EUA) from the U.S. FDA for its second-generation OraQuick Ebola 2.0 Rapid Antigen Test for use with whole blood in live patients

** The test can also be used in cadaveric oral fluid from individuals suspected to have had Ebola disease at the time of death

** It can detect all four Ebola viruses currently known to cause disease in humans: Bundibugyo, Zaire, Sudan, and Taï Forest, OSUR says

** More than 2,000 Ebola cases and nearly 1000 deaths have been recorded in Congo, with the epidemic is caused by the Bundibugyo strain of the virus

** Up to last close, stock rose 57% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.